By Ben Butkus

Fluidigm this week reported a 36 percent increase in fourth-quarter revenues and 32 percent increase in yearly revenues in its first financial results statement since its initial public offering last month.

In addition, CEO Gajus Worthington provided an update regarding the uptake of Fludigm's newest real-time PCR system and thermal cycler; and discussed the status of the company's fledgling diagnostics play.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.